RxDoctor Payments Data

Edwin Gumapas, MD

Psychiatry · Crystal Lake, ILNPI 1033101092

Payments from drug & device makers

$2,688in general payments, 2019–2025

Across 32 payments — averaging $84.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$651
  • Acadia Pharmaceuticals Inc$629
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$338
  • Alkermes, Inc.$335
  • Johnson & Johnson$221
  • E.r. Squibb & Sons, L.L.C.$122
  • plus $392 from 5 others

What the payments were for

  • Travel & lodging$181%
  • Food & beverage$2,62398%
  • Education$472%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,688 in reported general payments places this provider in the 80th percentile of 1,344 psychiatry providers in Illinois.

See all psychiatry providers in Illinois

Medicare billing

Part B allowed, 2024
$231,294
Medicare patients
383
Services billed
1,979

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Austedo XrDeutetrabenazine60$98,891
AustedoDeutetrabenazine39$95,936
Invega SustennaPaliperidone Palmitate12$36,490
RexultiBrexpiprazole55$31,869
Clozapine525$25,484
Chlorpromazine Hcl366$16,573
Risperdal ConstaRisperidone Microspheres11$14,720
Divalproex Sodium502$12,171
Aripiprazole88$11,202
Quetiapine Fumarate1,221$8,196
Mirtazapine1,101$6,010
Memantine Hcl330$5,732
Fluphenazine Hcl371$5,712
Risperidone851$4,611
Trazodone Hcl887$4,325

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo$122$194,82799 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$221$51,21023 claims
Otsuka America Pharmaceutical, Inc.Rexulti$122$31,86955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,344 psychiatry providers in Illinois.

Other psychiatry in Crystal Lake

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →